STRATEGIC NEWS WATCH — July 10, 2026
|
Roche discontinued two Ionis-partnered Huntington’s disease studies after tominersen missed its key efficacy objective and separately halted a trial of the more selective candidate RG6496 — a double setback that deepened a brutal session for Ionis, whose AstraZeneca-partnered Wainua also failed a Phase 3 ATTR-CM trial. Today’s top developments:
|
What to Watch
- Huntington’s pipeline shakeout — Roche’s exit from tominersen and RG6496 thins the antisense field and sharpens focus on uniQure’s AMT-130 gene therapy, heading toward a planned accelerated-approval filing; how the FDA treats its Phase 1/2 data will define the disease’s near-term trajectory.
- Ionis pipeline recovery — With Wainua’s ATTR-CM miss and the Huntington’s exits landing the same day, watch how Ionis reassures investors on its remaining wholly-owned and partnered programs and whether the ~24% drop marks a reset or a buying opportunity.
- Abivax obefazimod approval path — With $920 million secured through 2029, Abivax must convert capital into a credible regulatory and commercial timeline; any NDA submission date or advisory committee scheduling will test its go-it-alone thesis in a crowded IBD market.
- Ocrevus biosimilar competition — The Teva-Polpharma deal joins a growing queue of challengers to Roche’s ~$7 billion MS franchise; watch for how quickly biosimilar entrants reach the clinic and what that signals for neurology price erosion.
- FDA leadership stabilization — The pace at which vacant senior FDA roles are filled will determine whether policy modernization, including AI-assisted review, advances or stalls; new appointments will be parsed closely for signals on review philosophy and timelines.
This brief highlights the edition’s top stories. Read the full July 10, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.